TY - JOUR AU - da, Mota AU - Laurindo, IM AU - de, Carvalho AU - dos, Santos-Neto PY - 2010/09/13 Y2 - 2024/03/28 TI - Prognostic evaluation of early rheumatoid arthritis JF - Swiss Medical Weekly JA - Swiss Med Wkly VL - 140 IS - 3738 SE - Review article: Biomedical intelligence DO - 10.4414/smw.2010.13100 UR - https://smw.ch/index.php/smw/article/view/1189 SP - w13100 AB - <p><p>The progression of rheumatoid arthritis (RA) is quite variable, ranging from very mild or subclinical forms (approx. 10%) to rapidly progressing and debilitating forms (10–15%). The majority of patients present with an intermediate stage with episodes of exacerbation separated by periods of relative inactivity, which evolves to progressive functional losses. To optimise the therapeutic management of early RA it is necessary to perform periodic evaluations of the clinical and laboratory test responses to the treatment instituted, as well as the parameters indicating disease prognosis. Composite measures are frequently used to evaluate the disease activity score (DAS), including the response criteria of the American College of Rheumatology (ACR), the response criteria and the DAS according to the European League Against Rheumatism (EULAR) and the composite indices of disease activity (CIDsA): DAS, the index of disease activity based on 28 joints (DAS 28), the simplified disease activity index (SDAI) and the clinical disease activity index (CDAI). The evaluation of prognosis includes investigation of the absence or occurrence of disease and joint damage remission. Due to the multifaceted nature of RA, no single clinical or laboratory parameter is able to describe satisfactorily the level of inflammatory activity or the disease prognosis at any given time.</p></p> ER -